Mutations in the epidermal growth factor receptor (EGFR) gene are predictive of the response to EGFR tyrosine kinase inhibitor (TKIs) therapies. The ViennaLab StripAssay^® identifies 30 EGFR mutations relevant for non-small cell lung cancer (NSCLC) TKI therapies.

EGFR

• NSCLC comprises approximately 85% of all lung cancers. Tumor specimens from patients should be tested for the presence of EGFR mutations prior to TKI treatment.
• Patients carrying EGFR mutations known as `activating mutations´ may benefit from first- or second- or third-generation TKIs. Patients carrying the `resistance mutation´ EGFR T790M may benefit from third-generation TKI.
• The EGFR XL StripAssay^® is designed to assist clinicians in the stratification of patients considered for TKI therapy.